Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

被引：39

作者：

Janjigian, Y. Y. ^{[1
]}

Al-Batran, S-E. ^{[2
]}

Wainberg, Z. A. ^{[3
]}

Van Cutsem, E. ^{[4
,5
]}

Molena, D. ^{[6
]}

Muro, K. ^{[7
]}

Hyung, W. J. ^{[8
]}

Wyrwicz, L. S. ^{[9
]}

Oh, D. Y. ^{[10
,11
]}

Omori, T. ^{[12
]}

Moehler, M. ^{[13
]}

Garrido, M. ^{[14
,15
]}

Oliveira, S. Cunha Sousa ^{[16
]}

Liberman, M. ^{[17
]}

Oliden, V. Castro ^{[18
]}

Bilici, M. ^{[19
]}

Kurland, J. F. ^{[20
]}

Xynos, I. ^{[21
]}

Mann, H. ^{[21
]}

Tabernero, J. ^{[22
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, New York, NY USA

[2] Univ Canc Ctr, Inst Clin Canc Res, Krankenhaus Nordwest, Frankfurt, Germany

[3] UCLA, David Geffen Sch Med, Dept Gastrointestinal Med Oncol, Los Angeles, CA USA

[4] Univ Hosp Leuven, Dept Gastroenterol Digest Oncol, Leuven, Belgium

[5] Katholieke Univ Leuven, Leuven, Belgium

[6] Mem Sloan Kettering Canc Ctr, Div Thorac Surg, New York, NY USA

[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[8] Yonsei Univ, Dept Surg, Coll Med, Seoul, South Korea

[9] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland

[10] Seoul Natl Univ Hosp, Div Med Oncol, Dept Internal Med, Seoul, South Korea

[11] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea

[12] Osaka Int Canc Inst, Dept Gastroenterol Surg, Osaka, Japan

[13] Johannes Gutenberg Univ Clin, Res Ctr Immunotherapy FZI, Mainz, Germany

[14] SAGA Clin Trial Ctr, Hemato Oncol Dept, Santiago, Chile

[15] Univ Mayor, Santiago, Chile

[16] Clin Res Ctr, Northern Riograndense League Canc, Clin Oncol, Natal, RN, Brazil

[17] Ctr Hosp Univ Montreal Ctr Rech CHUM, Dept Surg, Div Thorac Surg, Montreal, PQ, Canada

[18] Natl Inst Neoplast Dis INEN, Med Oncol Dept, Lima, Peru

[19] Ataturk Univ, Dept Med Oncol, Fac Med, Erzurum, Turkiye

[20] AstraZeneca, Oncol R&D, Late Stage Dev, Gaithersburg, MD USA

[21] AstraZeneca, Oncol R&D, Late Stage Dev, Cambridge, England

[22] UVic UCC, Vall Hebron Hosp Campus & Inst Oncol VHIO, Dept Med Oncol, IOB Quiron, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.074

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA73

引用

页码：S1315 / S1316

页数：2

共 50 条

[1] Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Moehler, Markus
Janjigian, Yelena
Al-Batran, Salah-Eddin
Wainberg, Zev
Van Cutsem, Eric
Molena, Daniela
Muro, Kei
Hyung, Woo Jin
Wyrwicz, Lucjan
Oh, Do-Youn
Omori, Takeshi
Garrido, Marcelo
Sousa, Oliveira Sulene Cunha
Liberman, Moishe
Oliden, Victor Castro
Bilici, Mehmet
Kurland, John F.
Xynos, Ioannis
Mann, Helen
Tabernero, Josep
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 229 - 229
[2] Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Oh, D-Y.
Janjigian, Y. Y.
Al-Batran, S-E.
Wainberg, Z. A.
van Cutsem, E.
Molena, D.
Muro, K.
Hyung, W. J.
Wyrwicz, L. S.
Omori, T.
Moehler, M.
Garrido, M.
Cunha Sousa Oliveira, S.
Liberman, M.
Castro Oliden, V.
Bilici, M.
Kurland, J.
Xynos, I.
Mann, H.
Tabernero, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1520 - S1521
[3] PATHOLOGICAL COMPLETE RESPONSE (PCR) TO DURVALUMAB PLUS 5FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND DOCETAXEL (FLOT) IN RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER (GC/GEJC): INTERIM RESULTS OF THE GLOBAL, PHASE 3 MATTERHORN STUDY
Molena, Daniela
Janjigian, Yelena
Al-Batran, Salah-Eddin
Wainberg, Zev A.
Van Cutsem, Eric
Muro, Kei
Hyung, Woo J.
Wyrwicz, Lucjan
Oh, Do-Youn
Omori, Takeshi
Moehler, Markus
Garrido, Marcelo
Oliveira, Sulene C.
Liberman, Moishe
Oliden, Victor Castro
Bilici, Mehmet
Kurland, John F.
Xynos, Ioannis
Mann, Helen
Tabernero, Josep
GASTROENTEROLOGY, 2024, 166 (05) : S996 - S996
[4] Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study
Janjigian, Yelena Y.
Al-Batran, Salah-Eddin
Wainberg, Zev A.
Van Cutsem, Eric
Molena, Daniela
Muro, Kei
Hyung, Woo Jin
Wyrwicz, Lucjan S.
Oh, Do-Youn
Omori, Takeshi
Moehler, Markus
Garrido, Marcelo
Oliveira, Sulene C. S.
Liberman, Moishe
Castro Oliden, Victor
Bilici, Mehmet
Kurland, John F.
Xynos, Ioannis
Mann, Helen
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 245 - 246
[5] MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
Janjigian, Yelena Y.
Van Cutsem, Eric
Muro, Kei
Wainberg, Zev
Al-Batran, Salah-Eddin
Hyung, Woo Jin
Molena, Daniela
Marcovitz, Michelle
Ruscica, Dario
Robbins, Scott H.
Negro, Alejandra
Tabernero, Josep
FUTURE ONCOLOGY, 2022, 18 (20) : 2465 - 2473
[6] Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study
Janjigian, Yelena Y.
Al-Batran, Salah-Eddin
Wainberg, Zen A.
Van Cutsem, Eric
Molena, Daniela
Muro, Kei
Hyung, Woo Jin
Wyrwicz, Lucjan
Oh, Do-Youn
Omori, Takeshi
Moehler, Markus
Garrido, Marcelo
Oliveira, Sulene C. S.
Liberman, Moishe
Oliden, Victor C.
Bilici, Mehmet
Kurland, John
Xynos, Ioannis
Mann, Helan
Tabernero, Josep
ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S44 - S45
[7] MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer
Janjigian, Y.
Van Cutsem, E.
Muro, K.
Wainberg, Z.
Al-Batran, S.
Hyung, W.
Molena, D.
Evans, B.
Ruscica, D.
Robbins, S.
Negro, A.
Tabernero, J.
ANNALS OF ONCOLOGY, 2021, 32 : S118 - S118
[8] Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR)
Mélanie Dos Santos
Justine Lequesne
Alexandra Leconte
Stéphane Corbinais
Aurélie Parzy
Jean-Marc Guilloit
Sharmini Varatharajah
Pierre-Emmanuel Brachet
Marine Dorbeau
Dominique Vaur
Louis-Bastien Weiswald
Laurent Poulain
Corentin Le Gallic
Marie Castera-Tellier
Marie-Pierre Galais
Bénédicte Clarisse
BMC Cancer, 22
[9] Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR)
Dos Santos, Melanie
Lequesne, Justine
Leconte, Alexandra
Corbinais, Stephane
Parzy, Aurelie
Guilloit, Jean-Marc
Varatharajah, Sharmini
Brachet, Pierre-Emmanuel
Dorbeau, Marine
Vaur, Dominique
Weiswald, Louis-Bastien
Poulain, Laurent
Le Gallic, Corentin
Castera-Tellier, Marie
Galais, Marie-Pierre
Clarisse, Benedicte
BMC CANCER, 2022, 22 (01)
[10] Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome
Atci, Muhammed M.
Secmeler, Saban
Sakin, Abdullah
Arici, Serdar
Can, Orcun
Selvi, Oguzhan
Cekin, Ruhper
Yasar, Nurgul
Geredeli, Caglayan
Cihan, Sener
INDIAN JOURNAL OF CANCER, 2024, 61 (04) : 714 - 721

← 1 2 3 4 5 →